NCT00234481TerminatedPhase 1
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL844 Administered Orally to Subjects With Chronic Lymphocytic Leukemia
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Terminated
- Sponsor
- Exelixis
- Locations
- 6
Study Overview
Brief Summary
The purpose of this study is to assess the safety and tolerability of different doses of XL844 when given orally to adults with recurrent or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients with recurrent or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
- •Prior treatment with at least 2 systemic chemotherapy regimens for CLL
- •Life expectancy of >3 months
- •Adequate liver and kidney function
- •Absolute neutrophil count ≥500/mm3; platelets ≥50,000/dL; hemoglobin ≥9 g/dL
- •Willing to use accepted method of contraception during the course of the study
- •Negative pregnancy test (females)
- •Written informed consent
Exclusion Criteria
- •Chemotherapy or radiotherapy within 4-6 weeks of the start of treatment (depending on the therapy)
- •Investigational drug within 30 days of the start of treatment
- •Uncontrolled intercurrent illness such as infection or cardiovascular disease
- •Pregnant or breastfeeding women
- •Subjects known to be HIV positive
Investigators
Study Sites (6)
Loading locations...
Similar Trials
Terminated
Phase 1
Safety Study of Pharmacokinetics of XL888 in Adults With Solid TumorsCancerNCT00796484Exelixis33
Withdrawn
Phase 1
Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid TumorsNon-small-cell Lung CancerCancerBreast CancerNCT00704392Exelixis
Suspended
Phase 1
Study of XL418 in Adults With Solid TumorsSolid TumorsCancerNCT00460278Exelixis63
Completed
Phase 1
Study of XL184 (Cabozantinib) in Adults With Advanced MalignanciesCancerLymphomaThyroid CarcinomaNCT00215605Exelixis85
Terminated
Phase 1
A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced MalignanciesCancerLymphomaNCT00475917Exelixis28